Superworth

Twist Bioscience EPS TWST

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$2.22
Latest quarter, Q3 FY26
−$0.56
−270% on a year earlier
Fiscal year 2025
−$1.31

Twist Bioscience's earnings per share was −$2.22 over the twelve months to Jun 30, 2026.

In its latest quarter, Q3 FY26, it was −$0.56, down 270% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.31n/a
FY2024−$3.60n/a
FY2023−$3.60n/a
FY2022−$4.02n/a
FY2021−$3.16n/a
FY2020−$3.76n/a
FY2019−$3.99n/a
FY2018−$25.50n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.56−270%−$2.22
Q2 FY26−$0.71n/a−$1.33
Q1 FY26−$0.50n/a−$1.28
Q4 FY25−$0.45n/a−$1.31
Q3 FY25$0.33n/a−$1.45
Q2 FY25−$0.66n/a−$3.25
Q1 FY25−$0.53n/a−$3.38
Q4 FY24−$0.59n/a−$3.60
Q3 FY24−$1.47n/a−$3.82
Q2 FY24−$0.79n/a−$3.36
Q1 FY24−$0.75n/a−$3.61
Q4 FY23−$0.81n/a−$3.60

Against its peers

Companies in Biotechnology nearest Twist Bioscience's size, closest first, today.

CompanyEPS, 12 monthsGrowth
TWSTTwist Bioscience−$2.22
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
ALNYAlnylam Pharmaceuticals$5.93
ADMAAdma Biologics$0.70−18% a year
Peer median$4.64

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Twist Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.